Second, although we did see significant upregulation of AVP in the ADPKD cohort as compared with the CKD group of patients, in follow-up studies we will probably also include measurements of copeptin, a peptide fragment of AVP [51], that was shown to be an even better biomarker than AVP itself. Here, AVP is linked to autosomal dominant polycystic kidney disease.